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The blood–brain barrier (BBB) is a complex physiological structure formed by the blood vessels of the central
nervous system (CNS) that tightly regulates the movement of substances between the blood and the neural tissue.
Recently, the generation and analysis of different genetic mouse models has allowed for greater understanding of
BBB development, how the barrier is regulated during health, and its response to disease. Here we discuss: 1)
Genetic mouse models that have been used to study the BBB, 2) Available mouse genetic tools that can aid in the
study of the BBB, and 3) Potential tools that if generated could greatly aid in our understanding of the BBB.
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Introduction
The blood–brain barrier (BBB) is a functional physio-
logical structure formed by the blood vessels of the cen-
tral nervous system (CNS) that tightly regulates the
exchange of molecules, ions and cells between the blood
and the CNS, and is critical for maintenance of homeo-
stasis within the nervous tissue. Many of the properties
of the BBB are possessed by the endothelial cells (ECs)
that form the walls of the blood vessels, and these prop-
erties are tightly regulated by both neural and immune
cells. Important BBB properties include: 1) CNS ECs are
joined together by tight junctions (TJs) which create a
paracellular barrier, 2) CNS ECs undergo extremely low
rates of transcytosis creating a transcellular barrier to
hydrophilic molecules, 3) CNS ECs express transporters to
efflux potential toxins from the CNS, 4) CNS ECs express
selective transporters to deliver specific nutrients to the
CNS, 5) CNS ECs express very low levels of leukocyte ad-
hesion molecules limiting the entry of immune cells into
the CNS. ECs interact with immune cells in the blood, as
well as different cells within the CNS parenchyma, inc-
luding pericytes, astrocytes, macrophages, microglia and
neurons, and these interactions are important to regulate
the formation of the BBB during development, the* Correspondence: Fabien.sohet@ucsf.edu; Richard.daneman@ucsf.edu
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distribution, and reproduction in any mediumfunction of the BBB during health, and the response of the
BBB to injury and disease.
In this review we will discuss mouse genetic models that
can be utilized to study the BBB during health and disease.
First we will discuss selected genetic models that have
been used to identify novel aspects of BBB function in-
cluding endothelial barrier function, CNS angiogenesis
and BBB development, and interactions of different cell
types within the neuro-vascular unit (see Additional file 1:
Supplementary Table 1. Genetic mouse models to study
the BBB). In the second section we will discuss current
genetic tools available for analysis of BBB function. In the
final section we will suggest several potential genetic tools
that if generated could greatly increase our ability to study
and understand the BBB.Types of genetic mouse models
In general, mouse genetic models fall under two categories:
gene silencing or ectopic gene expression (Figure 1). Pub-
lished mouse lines can be found in the Mouse Genomic
Informatics (MGI) data base (http://www.informatics.jax.
org/).
For gene silencing, the most common tools include
mouse knockout or conditional knockout technologies.
Mouse knockout models use homologous recombination
to delete a specific gene, or a section of a specific gene,
from its endogenous chromosomal locus. This techniqueCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 (See legend on next page.)
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Figure 1 Representation of genetic mouse models. 1) Knockout out of specific genes. A neomycin cassette is inserted by homologous
recombination either into an exon (1A) of a gene of interest or replacing the whole gene of interest (1B). 2) Methods to control the cell
specificity and timing of gene deletion. Homologous recombination is used to insert lox-p sites surrounding an exon of the gene of interest. To
conditionally delete the gene in a specific cell type, the Cre recombinase is expressed by a tissue specific promoter and deletes the loxP flanked
region (2A). To regulate the timing, one can use a transgene encoding a Cre recombinase fused with the modified estrogen receptor (Cre-ERT)
that will move into the nucleus upon injection of tamoxifen (2B). 3) Ectopic expression of a transgene. A common method is to utilize a lox-
stop-lox cassette which can be removed by Cre recombinase. A transgene is generated with a stop codon that is flanked with two loxP sites
upstream of the transgene of interest. The transgene can be introduced to the genome at a specific locus by homologous recombination or
randomly inserted in the genome. When the Cre recombinase deletes the stop codon, the transgene can be transcribed (3A). This technique is
available with the Cre-ERT system (3B). 4) To reversibly express a transgene. A common method is the use of the TRE/tTA or TRE/rtTA systems. A
transgene is generated with the gene of interest downstream of the tetracycline responsive element (TRE). A second transgene is generated
with a tissue specific promoter controlling the expression of tTA (Tet-Off, 4A) or rtTA (Tet-ON, 4B). For Tet-OFF, the tTA activates transcription of
the transgene downstream of the TRE promoter, only in the absence of doxycycline. For Tet-ON, the rtTA activates transcription of the transgene
downstream of the TRE promoter only in the presence of doxycycline.
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has widely been utilized to study the role of genes in
mouse development and function. For genes on the som-
atic chromosomes, each mouse receives a chromosome
from each parent, and thus one can create homozygous
knockout mice in which alleles on both parental chromo-
somes are mutated or heterozygous mice in which only
one allele is mutated. For genes on the sex chromosomes
the details are more complicated. For instance, males only
receive one X-chromosome from their mother, and thus
for genes on the X-chromosome males can be either mu-
tant or wild type, but not heterozygous. Females receive
an X chromosome from each parent, and thus can be wild
type, heterozygous or homozygous for mutant alleles,
however because of X inactivation, heterozygous mutation
can lead to mosaicism as a different X chromosome may
be inactivated in different cells.
More recently, generation of conditional mutant mouse
lines has allowed for spatial and temporal control over
gene silencing. Specifically, homologous recombination is
used to flank a critical exon (or exons) within a specific
gene with lox-p sites. The lox-p sites do not alter gene
function, but upon expression of a Cre recombinase gene,
the recombinase deletes the section of the gene flanked by
the lox-p sites. Therefore, expression of Cre-recombinase
by transgenics, viral infection or other methods can con-
trol the cell specificity of the gene deletion. Further con-
trol of the timing of gene deletion can be achieved by
using a CreERT or CreERT2 recombinase, in which the
recombinase is fused to a modified estrogen receptor and
thus is only targeted to the nucleus upon injection of tam-
oxifen [1]. Therefore use of the CreERT allows for spatial
control (where the CreERT is expressed) and temporal
control (when tamoxifen is injected) of gene deletion. The
Cre/lox systems irreversibly delete sequences flanked by
lox-p sites, and thus several different methodologies have
been used to deliver double-stranded RNA, either shRNA
or siRNA, to reversibly silence specific genes.
For ectopic expression, several techniques can be used
to introduce novel genetic sequences into the mousegenome, including homologous recombination into a
specific locus in the mouse genome, or random integra-
tion of transgenes through injection into an embryo.
These techniques have been used to express mutant
forms of genes, over-express genes, mis-express genes in
different cell types, express exogenous genes such as
GFP or LacZ reporters, or express toxins to kill specific cell
types [2]. Several methods have been used to control the
specificity of the expression of the transgenes (Figure 1).
The transgene can be generated downstream from a
defined promoter, and thus the expression will be con-
trolled by the specificity of the promoter. The transgene
can be generated downstream from a strong promoter and
a stop cassette that is flanked by lox-p sites (lox-stop-lox).
In this case, the stop cassette will inhibit the expression of
the gene, unless the cassette is excised by Cre recombinase,
and thus the onset of the expression is controlled by the
Cre recombinase, but expression is controlled by the up-
stream promoter once the lox-p sites have been removed.
Often the lox-stop-lox transgene cassette is inserted in the
ROSA locus by homologous recombination. The ROSA
locus has been shown to ubiquitously express genes, and
thus inserting a lox-stop-lox reporter cassette into this
locus marks all cells downstream of the cell in which the
cre-recombinase excision has occurred. Zambrowicz et al.
showed that insertion of the β-galactosidase gene at the
ROSA locus in mice induced a broad β-gal activity
throughout the body [3].
Another common technique utilized is to generate the
transgene downstream of the tetracycline response element
(TRE) (Figure 1). The TRE element promotes the expression
of genes when the reverse tetracycline transactivator (rtTA)
and doxycycline are both present. Therefore, spatial con-
trol of gene expression can be achieved by the expression
of rtTA in response to cell specific promoters, and tem-
poral expression can be reversibly achieved by altering the
levels of doxycycline in the diet. This method can also be
used with a tetracycline transactivator (tTA) that induces
expression from the TRE reporter when doxycycline is
removed from the diet. Additionally different methods of
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other techniques have been utilized to deliver genetic ma-
terial to specific cells in mice.
Mouse models used to study the BBB
Targeting endothelial cell function
Tight Junctions
CNS ECs differ from ECs in non-neural tissues in that
they are held together by TJs which greatly restrict the
paracellular movement of molecules and ions between
the blood and brain. Most of the TJ proteins have been
identified by work on epithelial cells, which has demon-
strated that TJs are formed by a series of transmembrane
proteins, including the claudins [4,5], occludin [6] and
junctional adhesion molecules (JAMS) [7] which are
linked to the cytoskeleton and adherens junctions by
adaptor molecules including ZO-1, ZO-2, Cingulin and
others. In particular, claudins are a family of >20 tetra-
spanin genes in mammals and expression of specific
claudin family members in different cellular barriers is
thought to be important for the specific paracellular
physiology of the barrier [8]. Claudin 5 has been identi-
fied as a major constituent of the TJs of CNS ECs
(Figure 2). Nitta and colleagues have generated Cldn5
knockout mice [9]. These mice die at birth, and embryos
have been shown to have a size selective leakiness of the
BBB, with leaks to small molecules (up to 800 Da) butFigure 2 Schematic representation of the BBB in health and diseases.
(left side) and during pathological breakdown during injury and disease (rig
with cells in the blood (RBC-red, leukocyte-blue) and in the neural tissue (p
during diseases such as stroke and MS.not large molecules (serum albumin, 68 kDa and micro-
peroxidase, 1.9 kDa). The BBB TJs look ultrastructurally
normal in the absence of claudin 5 suggesting that other
TJ proteins are sufficient to form the structural junc-
tions. In fact, claudin 3 and 12 have been identified as
being expressed by CNS ECs [10,11]. The Cldn5 knock-
out mouse strain is a complete knockout and thus this
mouse model cannot be utilized to study the cell au-
tonomous action of claudin 5 in CNS ECs.
Pfeiffer and colleagues have developed tools utilizing
the tTA/TRE system to ectopically express claudin 1 in
ECs [12]. This group used a double transgenic model in
which the tTA was expressed from the Tie2 pan-
endothelial promoter, and claudin 1 was expressed from
the TRE promoter, therefore claudin 1 would be ectopi-
cally expressed in ECs if the mouse diet lacks doxycyc-
line. They used this model to express claudin 1 in ECs
during neuroinflammation in experimental autoimmune
encephalomyelitis (EAE), a mouse model of multiple
sclerosis (MS) [13]. During EAE there is a breakdown of
the BBB which allows the entry of immune cells and
molecules into the CNS which attack the CNS myelin
causing damage to the CNS. This group showed that ec-
topic expression of claudin 1 seals the BBB during this
disease and lessens the symptoms of EAE.
Occludin is a tetraspanin found at TJs in all epithe-
lial cells, and has been identified as being expressedSchematic representation of the blood–brain barrier in health
ht side). CNS endothelial cells (pink) form BBB properties, and interact
ericyte-green, astrocytes-taupe). Many of the BBB properties are altered
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Ocln knockout mice, which are viable but the males are
infertile [15]. The TJs in the epithelial cells and CNS ECs
appear ultrastructurally normal in the Ocln knockout
mice, and the measurements of the electrical resistance of
the intestinal epithelial cells is also unperturbed, suggest-
ing that TJs form a functional barrier in the absence of
occludin. Interestingly, the Ocln knockout mice have calci-
fication of the brain suggesting that there could be specific
defects in the regulation of the paracellular movement of
calcium.
Transcytosis
Transcytosis is the process by which a vesicle is trafficked
through the cell from one surface to the other and it can
be accomplished through: a receptor-mediated mechanism
by specific binding from a ligand to its receptor, by a non
specific uptake called pinocytosis, or an adsorptive-
mediated mechanism initiated by electrostatic forces
between the negatively charged ECs membrane and posi-
tively charged proteins. CNS ECs undergo extremely low
rates of transcytosis compared with ECs in non-neural tis-
sues, which greatly limits the transcellular movements of
hydrophilic molecules between the blood and the brain.
An increase in the number of transcytotic vesicles in CNS
ECs has been observed in several diseases in which there
is breakdown of the BBB [16-18]. The vesicle-mediated
transport is primarily mediated through caveolin based
vesicles ([19] for review). Several groups have made Cav1
knockout mice, including a caveolin-1 conditional lox-p
flanked allele, however the complex phenotype in the mice
throughout the vascular network makes it very difficult to
study the role of caveolin-1 specifically at the BBB [20-25].
Plasmalemmal vesicle-associated protein-1 (PLVAP) is a
transmembrane protein associated with the caveolae of
fenestrated microvascular ECs [16]. In rodents, PLVAP ex-
pression is enriched in non-CNS ECs compared to CNS
ECs [26]. Interestingly, during diseases like ischemia/Figure 3 Abcb1a/Abcb1b/Bcrp triple knockout mice have a leaky BBB
knockout mice (3KO) were given an intravenous injection of Rhodamine12
transcardiac perfusion with PBS, the brains were removed, hemisected dow
Fujifilm imager LAS 4000. Figure 3 represents an image of the hemisected
towards the bottom of the image. More Rhodamine123 (dark color) was ob
littermate controls. To demonstrate the consistency of the phenotype betw
knockout mice brains were utilized.PLVAP1
stroke, acute ischemia, tumors or diabetic retinopathy,
PLVAP1 is upregulated in CNS ECs (Figure 2) [18,27,28].
both knockout and conditional alleles, however mutant
mice have not yet been described.
Efflux transport
CNS ECs express efflux transporters to eliminate poten-
tial toxins from the CNS. These include members of the
ATP-binding cassette (ABC) transporters, which utilize
the hydrolysis of ATP to transport a wide variety of sub-
strate molecules against their concentration gradient. In
particular, CNS ECs express P-glycoprotein (Pgp/Mdr1/
Abcb1) and the breast cancer resistance protein (Bcrp/
Abcg2) (Figure 2), each of which has diverse but poten-
tially overlapping substrate specificity [29-31]. The mouse
genome contains two Pgp genes: Abcb1a and Abcb1b.
Several mouse lines are available for studying Abcb1a,
including targeted gene disruption (Abcb1atm1bor), a Cre/
lox regulated luciferase targeted into the Abcb1a locus
(Abcb1atm1Kane) and a spontaneous mutation (Abcb1amds)
that has a long terminal repeat of the ecotropic murine
leukemia virus inserted into an intron [32-34]. Mice
homozygous for Abcb1atm1bor allele have a BBB that is
more permeable to specific molecules including different
xenobiotics and drugs [32]. Because Pgp has 2 isoforms,
Doran and colleagues generated a double knockout mouse
of Abcb1a and Abcb1b to study drug delivery [35]. Finally,
as Pgp and Bcrp can transport some of the same substrates,
the Abcb1a/Abcb1b/Bcrp triple knockout mouse was genet-
ically engineered [36] and found to have a leaky BBB for
many lipophilic xenobiotics, including rhodamine123, com-
pared to their wild type (WT) littermates (Figure 3). These
mice are very useful to study brain neuroprotection and
neurotoxicity [37]. However one has to keep in mind that
in these widely-used knockout strains, the efflux transpor-
ters are deleted in every cell throughout the body, and not
specifically in CNS ECs.
Mouse ES cell lines have been targeted for , forto Rhodamine123. Adult wild type (C) or Abcb1a/Abcb1b/Bcrp triple
3 (10 ng). After 1 hour the blood compartment was removed by
n the midline and imaged for Rhodamine123 fluorescence with a
brains with the cerebellum at the top of the image and frontal cortex
served in Abcb1a/Abcb1b/Bcrp triple knockout mice compared with
een different animals, 3 wild-type and 3 Abcb1a/Abcb1b/Bcrp triple
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CNS ECs express a series of solute transporters that
transport specific nutrients into the brain including: glu-
cose (GLUT1/Slc2a1), lactate (MCT1/Slc16a1), amino
acids (Slc7a1, Slc7a5) and others (for review see [38]).
Mouse null knockout models have been generated for a
number of different transporters, however these often
have phenotypes throughout the organism, as diverse
cell types often require transport of these nutrients. For
instance, Slc7a1 knockout mice die in the neonatal
period with severe anemia [39], whereas Slc7a5 knock-
out mice display embryonic lethality [40]. Therefore, for
many of these solute carriers it may be critical to de-
velop conditional alleles to specifically study their func-
tion at the BBB.
GLUT1 has been largely studied for its role in deliv-
ery of glucose to the CNS (Figure 2). Glucose is the
primary source of energy for the brain, and human
GLUT1 deficiency results in an epileptic syndrome. A
Glut1 knockout allele has been generated with targeted
disruption of the promoter and exon1 of the gene [41].
Mice homozygous for this allele die during embryogen-
esis with pleiotropic phenotypes, whereas mice hetero-
zygous for this Glut1 mutation display a 66% decrease
of GLUT1 protein in the brain, and have similar symp-
toms as the GLUT1 deficiency syndrome found in
humans including epileptic events and impaired motor
activity. A second group used a gene-trap method to
disrupt the Glut1 locus [42]. For this gene-targeting
model, the trapping vector contains a splice acceptor site
along with the neomycin coding sequence and a polyade-
nylation sequence, and thus when inserted into the Glut1
locus, the upstream Glut1 sequence is spliced to the
trapped sequence forming a truncated mRNA. Following
the polyadenylation sequence, the vector also contains a
Bruton’s tyrosine kinase (btk) gene with a splice donor site,
and thus a fusion mRNA is expressed with the Btk mRNA
fused to the downstream Glut1 sequence. Mice homozy-
gous for this gene trap demonstrated embryonic lethality,
whereas heterozygous mice displayed no phenotype. The
difference in phenotype observed between the Glut1 he-
terozygotes generated from these two studies may be due
to the differing affects of the targeting on gene expression,
or compensation from other transporters such as the
monocarboxylic acid transporters MCT1 and MCT2. A
lox-p flanked conditional Glut1 allele has now been gener-
ated that can be utilized to study GLUT1 in specific cell
types, such as CNS endothelial cells [43]. In addition, Hei-
lig and colleagues developed a transgenic mouse line in
which the expression of antisense-GLUT1 sequence was
driven from the b-actin promoter in order to knockdown
the glucose transporter during development [44]. Hemizy-
gous or homozygous embryos for this transgene display
reduced glucose uptake.Leukocyte adhesion
The healthy CNS has an extremely low level of immune
surveillance with the almost complete absence of subsets
of leukocytes including neutrophils, T-cells and B-cells,
however changes to the BBB during diseases including
multiple sclerosis (MS), stroke, and neurodegenerative
disorders can allow entry of immune cells into the CNS
which is an important component of the pathogenesis of
these diseases. Entry of immune cells into a tissue is a
multi-step process that involves the binding of a series
of adhesion molecules expressed on the immune cells to
adhesion molecules on the post-capillary venule ECs
[45]. This process involves tethering of the leukocyte to
the endothelium, rolling along the endothelium, activation
of the leukocyte, firm adhesion to the endothelium, and
transmigration between or through the ECs. Several adhe-
sion molecules on the endothelium have been identified,
including P-Selectin and E-Selectin for rolling adhesion,
and Icam1 and Vcam1 for firm adhesion (Figure 2). The
expression of these adhesion molecules is low in healthy
CNS ECs, but can be dramatically upregulated during in-
jury and disease.
Several genetic mouse models have been developed to
study leukocyte adhesion and transmigration in different
models for CNS diseases. This review focuses on the dif-
ferent genetic manipulations of the BBB, however here we
briefly introduce a few of the disease models in which BBB
dysfunction is commonly analyzed. MS is an inflammatory
demyelinating disease of the CNS with numerous neuro-
logical symptoms that can lead to physical and/or cogni-
tive disability. The most common animal model of MS
used to study its immune and inflammatory components
is called experimental autoimmune encephalomyelitis
(EAE). The disease is induced by immunization of a mye-
lin peptide (such as MOG) emulsified in an adjuvant that
will induce the inflammatory response, with pertussis
toxin often used to facilitate the induction of EAE. A
stroke is a loss of function of brain cells caused by an al-
teration of blood flow, most of the time in a cerebral ar-
tery, that limits the supply of oxygen and glucose to
specific regions of the CNS (ischemia). Many studies fo-
cussing on ischemic stroke use the middle cerebral artery
occlusion (MCAO) model. In this model the middle cere-
bral artery is ligated for minutes or hours which then may
or may not be followed by a release of the ligation leading
to reperfusion of the injured tissue. In addition, mouse
models for different neurodegenerative diseases with BBB
dysfunction are often utilized including amyotrophic lat-
eral sclerosis, Alzheimer’s disease and Parkinson’s disease.
Knockout mice for P-selectin or its ligand PSGL-1 have
been used to study leukocyte migration in neurological dis-
ease. In a stroke model, P-selectin knockout mice demon-
strate decreased BBB breakdown to gadolinium and IgG as
well as less infiltrating polymorphonuclear leukocytes [46].
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attenuated seizures suggesting that leukocyte CNS infiltra-
tion was an important component of the disease [47]. On
the other hand P-selectin knockout or PSGL-1 knockout
did not affect the disease severity in several different EAE
models [48-50]. E-selectin knockout mice have also been
generated and have defects in neutrophil infiltration in dif-
ferent tissues that are exacerbated when combined with P-
selectin knockout mice [51], but in an EAE model defi-
ciency in E-selectin does not affect the progression of the
disease [50]. However E-selectin knockout mice have not
been extensively utilized to study neurological disease.
Firm adhesion is mediated through binding of CD11/
CD18 and αVβ1 integrins on leukocytes to EC Icam1 and
Vcam1, respectively. Icam1 is an adhesion molecule com-
posed of repeating immunoglobulin-like domains, and
several different gene disruption strategies have been engi-
neered to develop Icam1 knockout mice including the
Icam1tm1Jcgr allele which disrupts exon 4 (Ig domain 3)
[52], the Icam1tm1Bay allele which disrupts exon 5 (Ig do-
main 4) [53], or Icam1tm1Alb allele which deletes the entire
coding sequence [54]. Whereas the Icam1tm1Alb allele
lacks all Icam1 isoforms, the Icam1tm1Jcgr and Icam1tm1Bay
alleles each produce specific alternatively spliced Icam1
isoforms. Therefore comparing the phenotype of each
knockout mouse can identify roles for different Icam1 iso-
forms. Interestingly, during EAE, Icam1 null mice (harbor-
ing Icam1tm1Alb alleles) have attenuated disease symptoms
[55], whereas mice with Icam1tm1Bay alleles had worse
EAE symptoms [55,56]. These data suggest that specific
isoforms of Icam1 may have differing functions in regulat-
ing neuroinflammation. Furthermore, Hu et al. used adop-
tive transfer of encephalitogenic T-cells from wild type to
mutant strain or vice versa to determine the cell autono-
mous function of these isoforms [55]. Vcam1 knockout
mice have also been generated and die during embryogen-
esis [57], however several lox-p flanked alleles have been
generated in order to study the postnatal and cell specific
function of Vcam1 [58-61].
Several adhesion molecules have been identified that
regulate the adhesion of specific subsets of leukocytes to
the endothelium. For instance, Th17 cells express MCAM
which binds to laminin 411 on the EC basement membrane
[62], CD4+ lymphocytes express CD6 which binds to EC
ALCAM [63], and ninjurin-1 on myeloid cells homotypi-
cally interacts with ninjurin-1 on inflamed ECs [64]. Mouse
knockouts for Alcam [65] and Mcam (Mcamtm1Lex) have
been generated, however these knockout models have not
been extensively utilized to study neurological disease.
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are secreted zinc-
dependent endopeptidases that can degrade components
of the extracellular matrix. Twenty-eight MMP familymembers have been reported so far, but in particular
MMP2, MMP9 and MMP12 have been suggested to play
a key role during CNS disease by disrupting the BBB. By
deleting Mmp2 or Mmp9, researchers have found that
the mice were protected after ischemia/reperfusion with
attenuated inflammation of the brain [66-68]. Recently
Mmp12 deficient mice have been studied during Thei-
ler’s murine encephalomyelitis (TME), a virus-induced
model of MS [69], and lack of MMP12 produced a re-
duction in macrophage infiltration and demyelination
with an intact BBB (Figure 2). It will be interesting to
define the role played by each MMP during different
neurological disorders.
CNS angiogenesis and BBB development
BBB development involves the complex interaction of
CNS cells with different neural and immune cells. The
process of BBB regulation begins with induction signals as
ECs invade the CNS during development and continues
with maintenance signals throughout life and ageing. Here
we discuss selected genetic models that have been used to
dissect this process including manipulating pathways that
affect angiogenesis (VEGF, Notch), CNS-specific angio-
genesis (Wnt/β-catenin, Gpr124), BBB maintenance (Shh,
Agt) and BBB ageing (ApoE) (Figure 2).
VEGF: Vascular endothelial cell growth factor (VEGF)
was first shown in 1989 to specifically activate EC prolif-
eration [70]. In mammals, 5 different VEGF molecules
have been discovered (VEGF-A, Placental Growth Factor
(PIGF), VEGF-B, VEGF-C, VEGF-D), as well as three
distinct receptors (VEGF-R1/Flt-1, VEGF-2/Flk-1/Kdr
and VEGFR-3/Flt-4) [71]. Mice knockout models have
been developed for each ligand and receptor, and condi-
tional alleles have been generated for VEGF-A, Flt-1 and
Kdr. VEGF-A, a paracrine factor, and its endothelial
receptors Flt-1 and Flk-1 are the most extensively char-
acterized members, and mice homozygous for null
alleles of each gene are embryonic lethal [72-75]. By
studying mice with a lox-p flanked conditional mutant
allele for VegfA in conjunction with a Nestin-Cre allele
to delete VegfA in the neural precursors, it was demon-
strated that the level of vascularity in the developing
brain is dependent on levels of VEGF-A [76,77]. PGF
has been less studied than VEGF-A but it has been
shown to play a critical role in vessel stabilization under
pathological events [78], and recently Freitas-Andrade et
al. developed a mouse deficient for Pigf [79]. This group
showed that after a hypoxic event the Pigf knockout
mouse displayed a delayed angiogenic response and an
increased BBB permeability to endogenous fibrinogen.
All the studies using mouse knockout models for VEGF
family members point out its critical role in angiogenesis
throughout the body including the CNS.
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mechanism that is best known for its function in cell-
fate decision in various tissues [80]. In mammals four
Notch receptors and five ligands have been identified
with diverse expression patterns [81]. In mouse embryos
Notch1 and Notch4 are predominantly expressed on the
arterial endothelium. When the Notch1 gene is inacti-
vated specifically in the endothelium, mutant embryos
die at embryonic day E10.5 with normal vasculogenesis
but important defects of angiogenesis [82]. Notch4-
deficient mice exhibit normal development without any
vascular abnormality [83]. However, the double Notch1/
Notch4 mutant mice have vascular defects more severe
than the single Notch1 mutant suggesting overlapping
functions of both receptors during development [83-85].
By using the Tie2-tTa system coupled with the TRE-
caNotch4, a constitutively active Notch4 mutant was
specifically expressed in the endothelium of postnatal
mice [27]. These mice show abnormal connections be-
tween arteries and veins associated with ectopic expres-
sion of the arterial marker ephrin B2 in veins. Activation
of constitutively active Notch4 in the blood vessels of
the developing mouse brain induces vessel enlargement
followed by hemorrhages in the cerebellum and the neo-
cortex, neurological damage and death [86].
Four of the 5 known Notch ligands (Delta-like 4 (Dll4),
Dll1, Jagged1 and Jagged2) are specifically localized in ar-
terial but not in the venous endothelium [81,83,87]. During
early vascular development, Dll4 share the same expression
pattern as Notch1 and Notch4 [83]. Homozygous and het-
erozygous gene inactivation of Dll4 leads to embryonic
lethality in several mouse strains between embryonic days
E9.5 and E10.5 due to severe vascular deffects [88,89].
However, in the outbred ICR strain, the heterozygous mu-
tation leads to limited embryonic lethality [88,89]. There-
fore, by using Dll4+/− mice retinas in the ICR strain, it was
shown that absence of one Dll4 allele leads to an increase
of endothelial tip cells that sense and respond to guidance
cues during angiogenesis [90-92]. Moreover, Hellstrom et
al. demonstrated a similar phenotype when Notch1 gene
was inactivated specifically in ECs, suggesting that during
angiogenesis, signaling through Dll4/Notch1 is responsible
for the regulation of endothelial tip cell formation [90] in
response to VEGF [90-92]. Although Dll1 is not involved
in arterial cell fate, it has recently been shown to be
required for maintaining arterial identity by using a trans-
genic mouse line that inducibly deletes Dll1 in endothelial
cells [93].
Wnt/ β-catenin: Several groups have demonstrated that
Wnt/β-catenin signaling is specifically activated in CNS
ECs during development and is required for angiogen-
esis into the CNS as well as development of the BBB
[94-96]. Wnts are secreted ligands that bind to Frizzledreceptors at the cell surface, which leads to inactivation
of a protein complex that degrades β-catenin. Stabilized
β-catenin is then able to translocate to the nucleus and
activate transcription along with Lef1/Tcf complexes
[97]. A number of different genetic mouse models have
been used to analyze different aspects of Wnt/beta-catenin
signaling at the BBB [94,96]. Several transgenic Wnt re-
porter mouse lines have been generated that have cDNA
encoding a reporter protein (LacZ, GFP) downstream of
Wnt responsive DNA elements such as TCF binding sites
(for review see [98]). These Wnt reporter mice, including
TOP-Gal, BAT-Gal and TOP-Flash, have been used to
identify Wnt activity in CNS ECs (for review see [98]).
A number of mouse models have been developed to tar-
get β-catenin activity. Several groups have developed
endothelial-specific β-catenin knockout mouse lines using
Tie2-Cre and β-catenin lox-p flanked alleles [94,96,99].
This model has demonstrated that endothelial β-catenin is
required for angiogenesis into the CNS [94,96,99], and for
the expression of BBB-specific transporters such as GLUT1
[94-96]. There are several caveats to this approach of inhi-
biting Wnt signaling. First, Tie2-Cre/β-catenin mutants die
during early embryogenesis, and so while they have been
effective for studying early angiogenic events, they have
been less successful for studying BBB maintenance. To ad-
dress this concern, Liebner and colleagues utilized a Pdgfb-
CreERT2 allele to delete lox-p flanked β-catenin alleles in
endothelial cells at postnatal ages, to demonstrate that
β-catenin was required for sealing off the BBB [95].
Second, Tie2-Cre is also active in hematopoietic lineage
cells [100], so each time this line is used one has to be sure
that phenotypes are not due to changes in blood cells.
Third, β-catenin is not only required for transduction of
canonical Wnt signaling, but is also a component of the
adherens junctions, and thus it is difficult to gene-
rate conclusions specifically about Wnt signaling from
β-catenin mutants. In addition to conditional knockout
strategies, transgenics have been used to generate gain of
function β-catenin mouse alleles by generating a transgenic
β-catenin with exon3 flanked by lox-p sites, and thus when
exon3 is removed the mutant β-catenin is constitutively
active. Using Pdgfb-CreERT2/β-catenin loxp-exon3-loxp
mice, Liebner and colleagues were able to activate
β-catenin in the embryo and observe precocious BBB mat-
uration [95].
Several genetic models have been utilized to inhibit
other aspects of Wnt signaling, including analysis of
Wnt7a/Wnt7b double knockout mice as these are the
Wnts with the broadest expression pattern in the devel-
oping CNS [94,96]. These mice die at embryonic day
12.5 and have angiogenesis deficits in the CNS, vascular
malformations and hemorrhage. Due to the early embry-
onic lethality of Wnt7b mutants, Stenman and collea-
gues used a conditional approach by generating a mouse
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alleles in conjunction with a Nestin-Cre to delete Wnt7b
in the developing neuroepithelium [96]. These mice lived
longer than the complete double knockout of Wnt7a/
Wnt7b mice, and thus gave vital information about the role
of Wnts in regulating CNS vessel development. In
addition, there are many different positive (Wnt, β-catenin,
Tcf) and negative (Axin2, Apcdd1, APC, Dkk, sFRP) regu-
lators of Wnt signaling, and mouse knockout and over-
expression alleles have been generated for many of these
(reviewed [97]). Recently, Tam et al. showed the critical
role of both TROY and DR6 for CNS angiogenesis as
downstream target genes of the Wnt/β-catenin signaling
[101]. They showed that DR6 mutant mice display a lower
density of brain vasculature and a leaky BBB for Evan’s blue
dye, with a lower amount of ZO1 protein in adult mice. In
mouse embryos they observed hemorrhages in the fore-
brain with a leaky BBB for sulfo-NHS-biotin, coupled with
a lower vascular density in the hindbrain. To determine
the endothelial specificity of these phenotypes, Tam et al.
generated a mouse with Tie2-Cre and exon2 DR6 lox-p
flanked alleles, and described similar phenotypes to full
knockout mice suggesting that DR6 expression is required
specifically in endothelial cells. Troy knockout mice display
a mild leakage of the BBB for Evan’s blue.
Gpr124: Recently, several groups have generated mouse
knockouts for Gpr124, which displayed a disruption of
angiogenesis in the forebrain and ventral spinal cord with
localized malformations and hemorrhages, demonstrating
that this G-protein coupled receptor was required for
CNS-specific angiogenesis [102-104]. Using mice with
lox-p flanked conditional alleles and Tie2-Cre transgenes,
it was demonstrated that Gpr124 function is specifically
required in the ECs [102,104]. Interestingly, the phenotype
looks similar to that observed in theWnt7a/Wnt7b double
knockout mice, however it remains unclear whether
Gpr124 and Wnt signaling are connected.
Hedgehog: The Hedgehog (Hh) family, first characterized
in Drosophila [105], are secreted morphogens [106]
that play a major role in development including neur-
onal guidance and angiogenesis [107,108]. Three mem-
bers of the Hh family have been identified in mice: Sonic
Hedgehog (Shh), Desert hedgehog (Dhh) and Indian
hedgehog (Ihh). Shh acts by binding to Patched, which
leads to de-repression of Smoothened (Smo) which acti-
vates genes through the transcription factor Gli [106].
Chiang and colleagues have generated a knockout mouse
model for Shh [109]. Shh mutant mice display embryonic
lethality with embryos having abnormal anatomy in sev-
eral parts of the body including the brain and spinal cords.
In the CNS, when Shh is overexpressed in the dorsal
neural tube of embryos, Shh transgenic mice display ahypervascularization [110]. Alvarez and colleagues
described how the Hh pathway contributes to the main-
tenance of BBB functions [111]. They showed that E13.5
embryos of the Shh knockout mice display a lower amount
of junctional proteins in the brain capillaries than their
WT littermates. To study the role of the Shh pathway spe-
cifically in ECs, they generated endothelial-specific Smo
knockout mice by using a Tie2-Cre allele and a Smo lox-p
allele. The BBB of the mutant mice is permeable to serum
proteins, like fibrinogen, apolipoprotein B and immuno-
glubulins in E14 embryos and P19 mice and the BBB of
adult mice is permeable to exogenous compounds. The
BBB leakiness was explained by a significant decrease of
several TJ proteins including claudin 3, claudin 5, occludin
and ZO1 and a fragmented basement membrane. More-
over, Alvarez et al. demonstrated that Shh plays a key role
in the regulation of the pro-inflammatory response during
EAE. Altogether, these data suggest two major roles of the
Hh pathway by regulating BBB function and protecting
the brain from inflammation.
Renin-angiotensin: In the brain, the renin-angiotensin
system controls cerebral blood flow, memory and BBB
function (for review see [112]). Astrocytes express angio-
tensinogen (Agt), a precursor of angiotensins I-IV (Ang).
In a mouse model deficient for Agt, Kaninuma and col-
leagues demonstrated that two weeks after a brain cold
injury, the knockout mice still display a leaky BBB com-
pared to their WT littermates whose BBB was repaired
[113]. This phenotype was less critical when AngII or
AngIV was given to the Agt deficient mice suggesting
their critical involvement in vascular repair after an in-
jury. Moreover, the Agt mutant mice have a leaky BBB
for endogenous serum plasminogen and albumin and
express less occludin at the EC TJs [114].
ApoE: Several groups have identified apolipoprotein E
(apoE) as a key regulator of BBB leakiness [115,116].
ApoE is mainly expressed by glial cells in the CNS where
they mediate transport uptake of lipoproteins [117]. The
knockout mouse of ApoE has a leaky BBB in 2-week old
and adult mice [115,116] that increases during ageing
[118]. The pericytes of the ApoE knockout mice have a
higher amount of cyclopilinA (CypA), a proinflammatory
cytokine, and nuclear translocation of the NF-κB factor
that transcriptionally activates MMP9, which correlates
with a decrease of EC TJ proteins such as ZO1, occludin
and claudin 5 at the BBB [115]. Moreover pericyte
coverage of ECs is decreased as well as the length of the
capillaries. By generating a double knockout mutant that
targets ApoE and CypA genes, Bell et al. demonstrated a
rescue of the aforementioned phenotypes suggesting that
the over-expression of cypA in the ApoE knockout mice
was important for the BBB dysfunction [115].
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Pericytes are mural cells that incompletely surround the
abluminal surface of the capillary endothelium (Figure 2).
These cells are derived from the neural crest and regulate
angiogenesis, vascular remodeling, leukocyte trafficking
and the formation and function of the BBB [119-121]. The
binding of the ligand platelet-derived growth factor-BB
(PDGF-BB) to the platelet-derived growth factor receptor
β (PDGFRβ) is required for the generation and recruit-
ment of pericytes to CNS vessels as Pdgfb knockout mice
and Pdgfrb knockout mice completely lack CNS pericytes
[122,123]. These mice have altered vascular patterning,
dilations in the microvasculature, and form micro-
aneurysms that occasionally hemorrhage. The ability to
study the role of pericytes in BBB function is limited in
both Pdgfb knockout and Pdgfrb knockout mice as they
die shortly after birth, however the Pdgfrb knockout mice
have been utilized to demonstrate that pericytes are
required for BBB formation during embryogenesis and
that they regulate the BBB by inhibiting the expression of
EC genes that would make the vessels leaky [119,120].
Several groups have developed genetic models which
decrease PDGFBB signaling through PDGFRβ without
completely abolishing it. Tallquist and colleagues have
generated a series of hypomorphic alleles of Pdgfrb in
which different numbers of tyrosine residues, which are
normally auto-phosphorylated upon ligand binding, are
mutated to phenylalanine residues [124]. Using different
combinations of these hypomorphic alleles, they were
able to generate mice with different numbers of peri-
cytes. These mice have been used to demonstrate that the
relative number of pericytes is important for the perme-
ability of the BBB during development [120]. Furthermore,
Bell and colleagues used this model to demonstrate that
during ageing there was reduction in capillary perfusion
and BBB breakdown that led to neural degeneration [125].
Interestingly, whereas there are BBB defects in this model
during development and ageing, the BBB appears some-
what normal during adulthood. Several genetic models
have also targeted the ligand to attenuate PDGFB signal-
ing. Lindblom and colleagues developed mice in which the
retention motif of PDGFB was deleted, such that PDGFB
binding to extracellular matrix heparan sulphate proteo-
glycans was disrupted, and mice homozygous for this al-
lele had 26% of the pericyte coverage of WT mice [126].
In addition, Armulik and colleagues generated mice that
had lox-stop-lox human PDGFB transgene at the ROSA
locus, and thus could ectopically express human PDGFB
in ECs by using a Tie2-Cre mouse line [119]. Using a
Pdgfb null knockout mouse as a background, they could
express one or two alleles of the human PDGFB and thus
generate mice with attenuated signaling that had 40% and
72% the number of pericytes of WT mice. Using these
lines, Armulik et al. demonstrated that pericytes wererequired for BBB function in adults, and did so by inhibiting
the rates of transcytosis [119]. One interesting point is that
there is a slight difference in the phenotype of the mice
when signaling is attenuated by targeting Pdgfb or Pdgfrb.
The Pdgfrb hypomorphic mice have a leaky BBB during de-
velopment and ageing but relatively normal BBB as adults,
whereas the models attenuating Pdgfb have a leaky BBB as
adults. Several reasons could lead to these differences in-
cluding: strain of mice, environment of mice, total numbers
of pericytes, signaling of PDGFB through multiple recep-
tors, or localization of signals.
Goritz and colleagues utilized a specific GLAST-CreER/
RosaYFP line to fluorescently label a specific subtype of
pericytes, which they termed type A pericytes [127]. To
accomplish this, they utilized a mouse in which a lox-
stop-lox YFP cassette was introduced into the ROSA locus
by homologous recombination, and thus the YFP reporter
would be expressed in cells following the Cre-recombinase
mediated excision of the stop cassette. Using the GLAST-
CreER line, they demonstrated that upon injection of tam-
oxifen in adults, the YFP reporter was expressed in the
spinal cord in a subset of pericytes. They then demon-
strated that following a spinal cord injury these type A
pericytes migrated to the site of injury and formed the scar
tissue. This group also used a Glast-CreER/RASless mouse
line to inhibit cell division of the type A pericytes in the
spinal cord injury model [127]. Rasless mice have null
alleles for H-Ras and N-Ras and have K-Ras alleles flanked
by lox-p sites. The mice are generally normal, except cells
lack the ability to divide if Cre-recombinase mediated mu-
tation of K-Ras occurs. Using the Glast-CreER/RASless
mouse line coupled with tamoxifen injections in the adult,
they were able to generate mice in which type A pericytes
developed normally (as the CreER only excises the condi-
tional allele upon tamoxifen injection in the adult), but
failed to divide in the adult following a spinal cord injury
model. This group showed that division of type A pericytes
is required for scar formation following spinal cord injury.
In addition Li and colleagues manipulated TGF-β sig-
naling in ECs to generate a mouse model that had defi-
cits in endothelial-pericyte interactions [128]. This group
generated a CNS endothelial conditional mutant of
Smad4, a downstream mediator of TGF-β signaling, by
utilizing lox-p flanked Smad4 alleles and a SP-A-Cre
mouse line. They demonstrated that disruption of Smad4
in CNS ECs led to a mouse with defective pericyte cover-
age, intracranial hemorrhage and BBB breakdown.
Targeting astrocyte function
Astrocytes are a major glial cell type in the CNS that
send out highly ramified processes that ensheath both
synapses and blood vessels (Figure 2). It is thought that
in the rodent brain a single mature astrocyte can cover a
space between 20,000 and 80,000 μm3 and contacts
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two capillaries [129,130]. Astrocytes play an important
role in regulating neuronal metabolic homeostasis, syn-
apse formation, neurotransmitter processing, as well as
coupling neuronal function with cerebral blood flow (for
review see [131]). Transplantation studies and in vitro
studies have suggested that astrocytes are important regu-
lators of BBB function. When isolated from the brain, ECs
lose their BBB properties as shown by a decrease in their
trans-endothelial electrical resistance (TEER) [132]. When
co-cultured with astrocytes or astrocyte-conditioned
media their TEER increases significantly, suggesting that
astrocyte-secreted factors are involved in activating the
barrier properties of the BBB [132,133].
Several genetic models have been developed that ma-
nipulate astrocyte function (reviewed by Pfrieger and
Slezak 2012 [134]). To selectively ablate astrocytes, sev-
eral groups have induced ectopic expression of the
herpes simplex virus thymidine kinase (HSV-TK) in
astrocytes under control of either the human GFAP pro-
moter or the murine Gfap promoter [135-137]. On its
own HSV-TK does not affect cell viability. However, the
enzyme converts ganciclovir into ganciclovir monopho-
sphate, a nucleotide analogue which disrupts DNA repli-
cation. Therefore, cell division can be inhibited by
addition of ganciclovir to HSV-TK expressing cells [138].
Delaney and colleagues used ganciclovir to inhibit cell div-
ision of GFAP-positive cells in neonatal GFAP-HSV-TK
mice, and demonstrated that astrocyte reduction in new-
born pups results in ataxia, neuronal excitotoxicity and a
disorganization of Purkinje cells and radial glia [135].
Due to the wide scale effects of disrupting cell division
in all astrocytes, Tsai and colleagues recently developed
methods to deplete specific domains of astrocytes [139].
To accomplish this they generated a transgenic mouse
line such that a lox-eGFP-stop-lox-Diptheria toxin-A
(DTA) was expressed under the control of an astrocyte-
specific Aldh1L1-promoter. In this mouse, eGFP is
expressed in astrocytes, however following Cre mediated
recombination of the lox-p sites, eGFP is no longer
expressed, instead DTA is expressed which kills the cells.
By mating this line with transgenic mouse lines in which
Cre recombinase expression is driven from promoters
that mark regionally-specific subsets of neural progeni-
tors (Pax3-Cre, olig2-Cre). The authors were able to kill
astrocytes in specific domains of the spinal cord by
mating this line with transgenic mouse lines. For ex-
ample, by mating the lox-eGFP-lox-DTA mice with the
Pax3-Cre mice, the mutant line displayed variable peri-
natal lethality rates with a lower number of astrocytes in
the dorsal spinal cord, but without an increase in their
BBB permeability.
To study the role of reactive astrocytes during CNS
pathology, Sofroniews’ group utilized the GFAP-HSV-TKmice combined with ganciclovir treatment to ablate divid-
ing reactive astrocytes during disease models (for review
see [138]). This group showed that reactive astrocytes were
required for inhibiting neurite outgrowth, regulating neur-
onal survival and repairing the BBB following spinal cord
injury [140]. During EAE, astrocytes form a scar that sur-
rounds the blood vessels and mice with targeted ablation
of proliferative astrocytes exhibit a much higher number of
leukocyte infiltrations in the CNS parenchyma [141].
Aquaporin 4 (Aqp4) is a water channel protein mainly
expressed in astrocyte endfeet that ensheath CNS blood
vessels [142]. One function of Aqp4 is to facilitate water
movement into and out of the brain. During a middle
cerebral artery occlusion (MCAO), a mouse model of
stroke, Aqp4 deficient mice have a decreased cytotoxic
cerebral edema and therefore an improved neurological
outcome [143]. Saadoun et al. showed that Aqp4 defi-
cient mice have a morphologically and functionally nor-
mal BBB [144]. Therefore it appears that Aqp4 plays a
key role in brain swelling during pathology, but not in
normal BBB architecture.
Imaging BBB function
Being able to visualize the movement of different cell
populations in vivo in live mice is an important step in
understanding how cells interact in physiological set-
tings. This was made possible by the use of two-photon
microscopy that allows brain imaging in living animals
at a depth up to 1 mm. Several groups have utilized dif-
ferent genetic methods to label cells and proteins for im-
aging of CNS ECs and their interaction with the brain
and immune cells. Transgenic mice with GFP expressed
by the Tie2 promoter have been utilized to label ECs
in vivo. This technique has been used for microscopy,
and we also have been able to purify brain ECs from these
mice using fluorescence-activated cell sorting (FACS) and
performed microarray analysis of their gene expression
[26]. In addition, different subpopulations of ECs can be
labeled for in vivo time-lapse imaging. Murphy and collea-
gues utilized Ephrin-B2-H2BGFP mice to visualize the nu-
clei of arterial ECs to examine the dynamics of cells
during formation and regression of arterial venous mal-
formations [145]. This mouse has a transgene of his-
tone-2B fused to GFP that was inserted by homologous
recombination into the first exon of the ephrin-b2 gene,
and thus a nuclear GFP was expressed from the ephrin-
b2 promoter [146].
Several different genetic techniques have been utilized
to label different cell populations and analyze how they
interact with the BBB. Davolos and colleagues developed
methods to image the interactions of neurons and
microglia with blood vessels in the spinal cord [147].
They performed intravenous (IV) injection of a fluores-
cent dye (rhodamine-dextran) into transgenic mice
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microglia [148] or transgenic YFP-H line in which a YFP
transgene is driven by the thy1 promoter and thus
expresses YFP in a subset of neurons [149]. The IV
tracer labeled the blood inside the vessels and thus
enables visualization of the interaction of microglia with
the vessels over time. In the brain, Rangroo Thrane
et al. used this technique to visualize the movement of
eGFP-microglia during hepatic encephalopathy, a neu-
roinflammatory disease characterized by liver failure fol-
lowed by an opening of the BBB [150]. Several groups
have now utilized the microglia/macrophage reporter mice
in which they express GFP from the Cx3cr1 locus and RFP
from the Ccr2 locus, and thus have microglia labeled in
green and macrophages labeled in red [151-153]. In
addition different methods have been utilized to label
astrocytes (see [134] for review) and pericytes in vivo [127].
To understand the interaction of auto-reactive T-cells
with the BBB, an adoptive transfer model of EAE has
been utilized with the injection of GFP-expressing MBP-
reactive T-cells into mice [154,155]. This technique was
utilized to examine the interaction of the T-cells with
the vessels including arrest on the surface of the vessels,
crawling against the blood flow, diapedesis and scanning
of the abluminal surface for phagocytes [154]. Further-
more, this technique demonstrated that prior to entry
into the CNS, the T-cells go into lung lymphoid tissues
and lymph nodes to be activated. After their activation,
the T-cells go back to the blood stream and migrate to
the CNS parenchyma to induce clinical symptoms [155].
Other imaging methods, such as magnetic resonance
imaging (MRI), positron emission tomography (PET) or
X-ray microtomography, can be used to image blood
vessels and BBB function in wild type mice as well as
transgenic animals.
Valuable tools available to study the BBB
A number of different tools have been developed in
order to regulate gene expression in CNS ECs. To
knockdown gene expression in ECs, several different
models of the Cre/Lox system are available. One mouse
line that has been generated is a Tie1-Cre [156]. Tie1 is
a member of the Tie receptor family, and is essential for
angiogenesis during embryogenesis. The Tie1 promoter
drives gene expression in ECs from embryonic day E10
until birth but also in a small part of hematopoietic cells
and within some neuronal populations in the cortex and
hippocampus [156]. In parallel, Tie2-Cre mouse lines
were generated which is to date the most commonly uti-
lized line for gene excision in ECs [100]. The Tie2 pro-
moter drives a similar expression pattern than Tie1, in
all ECs with some hematopoietic cells, but it seems that
it can start as early as embryonic day E8.5 [157]. When
comparing both systems, some phenotypic differencescan be seen during embryogenesis and were explained
by the expression delay of Tie1 compared with Tie2
[158]. Although extensively used to delete lox-p alleles
in ECs, several caveats arise from analysis of Tie2-Cre
mice. First, Tie2 is turned on in hematopoietic precur-
sors, and thus although Tie2 is no longer expressed in
many blood cells, the Cre irreversibly deletes the lox-p
flanked alleles in the precursors. Therefore, when ana-
lyzing phenotypes using conditional alleles in con-
junction with Tie2-Cre, one must consider that the
phenotype may arise from the function of the allele in
ECs or hematopoietic lineage cells. Second, the Tie2-Cre
can also excise lox-p flanked alleles in the female germ-
line, and thus mating strategies must be used in which
the Tie2-Cre with the lox-p flanked alleles are passed
through male parents to ensure that a complete knock-
out is not generated.
Two different Flk-1-Cre lines are available, one that
shows Cre expression in both vasculature and muscle
lineages [159] whereas the second one does not have the
muscle expression but seems to have a weak expression
in quiescent endothelium [160]. A PECAM (CD31)-Cre
has been generated to drive expression in endothelium,
but is not extensively characterized [61]. A VE-cadherin
Cre has also been generated [161]. The major interest of
this Cre is that the promoter drives expression during em-
bryogenesis as well as adulthood. Nevertheless, a strong
VE-cadherin-Cre-driven expression starts later during em-
bryogenesis than the Tie2-Cre system, around embryonic
day E14.5 [161]. Recently, VWF-Cre and SP-A-Cre lines
have been developed suggesting specific expression of Cre
in CNS ECs, however these newly-generated lines have
not been exhaustively studied [128,162].
Several attempts have been made in generating tam-
oxifen inducible Cre lines targeted specifically to ECs. A
Tie2-CreERT2 transgenic mouse was genetically engi-
neered [163] and shows a highly specific expression of
lox-p flanked reporter transgenes in endothelial cells only
when mice were treated with tamoxifen. In addition, two
VE-cadherin-CreERT2 and a PDGFB-CreERT transgenic
mouse lines were generated to express the tamoxifen-
inducible CreERT(2) from EC promoters [164-167].
Several caveats have arisen with these systems. Firstly,
whereas these transgenic alleles seem to efficiently ex-
cise lox-p flanked alleles if tamoxifen is given to embry-
onic or neonatal mice, the efficiency of recombination
is often reduced during adulthood [166]. Furthermore,
the timing of tamoxifen injections and the age of ana-
lysis has to be carefully controlled to determine if blood
cells are also targeted.
In addition groups have generated Tie2-Tta or VE-
Cadherin-tTA transgenic mouse lines in order to express
TRE driven transgenes specifically in ECs [86,168]. One
major advantage of the tTA/TRE system is that it is
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line being fed to the transgenic mice it is possible to turn
on and turn off the TRE driven transgenes. Additionally,
Tie2-GFP mice have been utilized to visualize as well as
purify ECs from the CNS [26,169].
To reduce the amount of pericyte coverage on the
blood vessels, several groups have generated Pdgfb and
Pdgfrβ deficient mice, as well as hypomorphic alleles of
the ligand and receptor [119,126]. However, to date
there are only a few mouse models to delete gene ex-
pression in pericytes. The most common line is the
Pdgfrb-Cre [170] but the receptor is expressed by several
mesenchymal cell types. Recently, Feng et al. developed
a Ng2-CreERT to inducibly knockdown gene expression
in pericytes, but in the CNS Ng2 is also expressed in
oligodendrocyte precursor cells [171].
To deplete the brain of astrocytes, GFAP-HSV-TK and
diptheria toxin systems have been generated [138,139]. To
delete genes in astrocytes, there are a high number of
mouse Cre lines available by using either the Gfap, Glast,
Blbp, Gli, Nes, Cx30, CX43 or S100B promoters (for re-
view see [134]). Genetics tools are also available to induci-
bly knockout gene expression with the CreERT2 system.
Additionally, researchers have used non-genetic methods
to knockdown genes at the BBB. One promising technique
is the delivery of siRNA into brain ECs. By high pressure
tail-vein injection of a claudin 5 siRNA or by infecting a
brain region stereotactically with a virus that produces a
claudin 5 shRNA, Campbell et al. found that it was pos-
sible to knockdown Cldn5 gene expression in brain ECs
and consequently open the BBB to some extent [172-174].
They recently demonstrated that knocking down Cldn5 at
the mouse BBB leads to a decrease in cerebral edema after
traumatic brain injury [175]. Other groups showed efficient
delivery of exosome-associated siRNA [176] or nanoparti-
cles coupled probes [177] to the CNS. Finally, it is also
possible to use ultrashort pulsed laser [178] or ultrasound
coupled with MRI to disturb the BBB and deliver mole-
cules into the CNS [179].
Potential tools for analysis of the BBB
As the boom of mouse genetic analysis continues, we can
forecast that the generation of many novel mouse lines in
the upcoming years will continue to advance our under-
standing of BBB function. Here we suggest a small num-
ber of tools that will aid in our understanding of BBB
function during health and disease.
For BBB TJs, several interesting questions remain un-
answered. There are multiple claudin family members
expressed in CNS ECs, however it is unclear whether
each claudin has unique functions within the TJ or
whether each member provides an additive effect on
limiting the permeability of the vessels. Developing
knockout mice for each claudin expressed by CNS ECs,as well as double and triple cldn knockouts will allow us
to address these questions. In addition, cldn5 knockout
mice die shortly after birth and thus it is not clear what
the role of claudin 5 in the adult is or whether cldn5
knockout mice die specifically due to lack of claudin 5
protein in CNS ECs or in other cells in the organism.
Generation of a lox-p flanked cldn5 allele would allow
for temporal and spatial control of claudin 5 deletion to an-
swer these questions. Furthermore, the knockout models
are irreversible, and therefore generation of transgenic
doxycycline-regulated claudin 5 shRNA would develop a
model in which TJ protein expression could be reversibly
modulated. Moreover, additional TJ proteins, such as the
lipolysis-stimulated lipoprotein receptor (LSR) and tricellu-
lin, that have recently been discovered in epithelial cells,
have also been found to be enriched in CNS ECs compared
to endothelial cells in non-neural tissues [26]. These TJs are
expressed at the epithelial tricellular junction, where three
cells meet [180,181]. It would be interesting to create the
endothelial specific knockout of these TJs to understand
their role in BBB formation and/or maintenance.
Our understanding of many BBB transporters has re-
lied on the analysis of knockout mice in which the trans-
porter is deleted from every cell. For instance Abcb1a/
Abcb1b/BCRP triple knockout mice have been exten-
sively utilized to study the role of these genes in xeno-
biotic protection. However, these genes are expressed in
a variety of cell types in different tissues, and thus
complete knockout of these transporters would globally
change the localization of their substrates, and thus their
specific function at the BBB may be obscured. Gener-
ation of mice with lox-p flanked alleles of different
transporters would allow for analysis of their function
specifically at the BBB.
In this review, we described several Cre lines that tar-
get ECs, including Tie2-Cre, VE-Cadherin-CreERT2,
PDGFB-CreERT2, and others. Many of these Cre alleles
target all ECs, and therefore it would be helpful to gen-
erate Cre alleles and CreERT alleles that specifically tar-
get CNS ECs. To do so, one could take advantage of the
split-Cre system. In this system, the Cre is fragmented
into two non-functional fragments and becomes active
only when expressed in the same cells. Therefore, by
using two different promoters, one can drive Cre expres-
sion (or CreERT2) in a very specific cell type [182,183].
For instance splitting the Cre to be driven by VE-cad-
herin and Glut1 promoters would potentially allow for
the specific targeting of CNS ECs. In addition, very little
is known about the differences in the BBB at different
segments of the vascular tree, from arteries to arterioles
to capillaries to post-capillary venules to veins. Generat-
ing Cre, CreERT, and tTA lines that specifically target
individual segments of the vascular tree would be of
great use to the scientific community.
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pericytes by affecting PDGFBB/PDGFRβ signaling by gen-
erating knockout or hypomorphic alleles of pdgfb or
pdgfrb. These knockout models affect pericytes during de-
velopment, and thus it is not clear what the effect of acute
pericyte loss in adults would be. Therefore, developing a
genetic model to target pericytes in adults would allow us
to further understand the role of pericyte-EC interactions.
For instance, generating a Pdgfrb-rtTA allele coupled with
a TRE-DTA allele would allow for doxycycline inducible
ablation of Pdgfrb-positive cells. In this case doxycycline
could be delivered systemically to target all PDGFRβ posi-
tive cells, or locally, for instance in the retina to specifically
target retinal PDGFRβ positive pericytes, perhaps to
mimic the loss of retinal pericytes during diabetic retinop-
athy. In addition, generating Cre/CreERT alleles that target
specific subsets of pericytes would allow for the study of
the relative contribution of each subtype of pericytes.
Gortiz et al. identified that there were at least two types of
pericytes, termed type A and type B pericytes [127], and
were able to genetically mark type A pericytes with a
GLAST-CreERT allele, however no such line has been
developed to target type B pericytes. This might be more
difficult as the molecular signature of different pericyte
subtypes have not been described. The same can be said
for astrocytes for which the complex heterogeneity among
different subclasses of astrocytes is beginning to be under-
stood. Developing Cre-lines that target specific functional
subsets may be important for understanding the regional
specificity of BBB regulation.
Conclusions
The generation of mouse genetic models that target BBB
structure and function have allowed us to gain a great
deal of knowledge about this important physiological
structure. These include models that target specific cells
including ECs, pericytes and astrocytes, as well as identi-
fying specific genes that are important for BBB forma-
tion and function. As the boom in mouse genetics
continues we can expect the generation of many more
genetic models that will continue to aid in the advance-
ment of our understanding of the BBB.Additional file
Additional file 1: Supplementary Table 1. Genetic mouse models to
study the BBB.
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